Hyperglycemia in diabetes causes tissue damage through various mechanisms and contributes to diabetic complications ([@CIT0001]). Several lines of evidence indicate that these mechanisms are activated by a single upstream event: mitochondrial overproduction of reactive oxygen species (ROS). Therefore, oxidative stress is implicated as a major factor in the development of diabetes complications. Increased formation of advanced glycated end-products (AGEs) is one of the mechanisms that contribute to hyperglycemia\'s tissue damage ([@CIT0002]). Due to hyperglycemia in diabetes, reducing sugars react non-enzymatically with free amino groups of protein to form a diverse group of protein-bound moieties known as AGEs ([@CIT0003]). Plasma proteins modified by AGE precursors bind to AGE receptors on cells, such as macrophages, vascular endothelial cells, and vascular smooth muscle cells, and this binding induces the production of ROS, causing multiple pathological changes in gene expression ([@CIT0004]).

Some of the best chemically characterized AGEs in humans are pentosidine and carboxy methyl lysine (CML) ([@CIT0005]). Peripheral artery disease, a macrovascular complication of hyperglycemia of diabetes, has been strongly associated with serum malondialdehyde (MDA), an indicator of ROS, and with AGEs in type 2 diabetes (T2D) ([@CIT0006]). Dietary supplementation, with antioxidant phytochemicals, may be a successful strategy to reduce the risk of pathological complications ([@CIT0007]). Pomegranate *(Punicagranatum)* juice (PJ) possesses the highest antioxidant capacity when compared with the commonly consumed polyphenol-rich beverages ([@CIT0008]). PJ supplementation has been shown to ameliorate hypertension and reduce risk factors of atherosclerosis in a few clinical studies ([@CIT0009]--[@CIT0012]), and the effects of PJ consumption on AGEs have not previously been studied. The present randomized clinical trial was designed to explore the effects of 12-week PJ consumption on plasma AGEs (including pentosidine and CML) and oxidative stress on patients with type 2 diabetes.

Materials and methods {#S0002}
=====================

Patients and study design {#S0002-S20001}
-------------------------

This study was a randomized, double-blind, placebo-controlled trial. Forty-four patients (23 men and 21 women, age range 56±6.8 years), at least 1-year post-type 2 diabetes diagnosis, were selected based on their medical records in Iran Charity Foundation for Special Diseases and Health Center in Tehran, Iran. All the patients were taking oral hypoglycemic agents, and none were using insulin. In addition, patients were not smokers and not suffering from any other chronic diseases and, if female, were not taking estrogen or progesterone. At baseline, patients were stratified by gender and randomly assigned to one of the two groups: group A (PJ, *n*=22) and group B (Placebo, *n*=22). Random allocation of patients to treatment groups was performed by sequentially numbered containers. Randomization was performed by an assistant, and the group allocation was blinded for the investigator and participants. Written informed consent was obtained from all the patients. Ethical approval for the trial was obtained from Ethical Committee of National Nutrition and Food Technology Research Institute (Tehran, Iran). This clinical trial has been registered in the Iranian Registry of Clinical Trials at [www.irct.ir](http://www.irct.ir) (ID No: IRCT201206144010N8).

Intervention and compliance {#S0002-S20002}
---------------------------

At baseline, patients were stratified by gender and randomly assigned to consume 250 ml/day PJ, or a control beverage of similar color and energy content for 12 weeks. The study product was packaged in single-serving labeled bottles, so that neither subjects nor staff members were aware of treatment assignment. The subjects were asked not to change their dietary habits, physical activities, or drug regimens. The patients were contacted every week to evaluate compliance to intervention and inquire regarding possible side effects. Each patient was provided with a fixed number of PJ bottles and instructions to return the unused bottles at the end of the study. Based on the number of returned bottles by each patient, their compliance was determined, which was 90%. Patients were excluded from the analysis if they consumed \<90% of the packets, had changed their medication, or reported severe side effects. No adverse events were reported.

Measurements {#S0002-S20003}
------------

Each subject\'s weight was recorded, while wearing light clothing and no shoes, using digital scales to the nearest 100 g. Height was measured to the nearest 0.5 cm. Body mass index (BMI) was then calculated as weight (kg) divided by square of height (m). Dietary intakes of the subjects were assessed, using a 3-day dietary recall (2 weekdays and 1 weekend day) at baseline and at the end of 12 weeks. The patient\'s diets were analyzed by Nutritionist IV software (N Squared Computing, San Bruno, CA, USA).

Biochemical analysis {#S0002-S20004}
--------------------

At baseline and the end of 12-week intervention, 10 ml blood was collected from each patient after a 12--14 h overnight fast. Blood samples to which the anti-coagulant was added were centrifuged at 4,000 rpm for 10 min. The plasma samples were separated into aliquots and were frozen at −80°C, until they were assayed.

Fasting plasma glucose (FPG) concentration was assessed using the colorimetry method by commercial kit (Pars Azemoon, Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, The Netherlands). Hemoglobin A1c (HbA1c) was assessed using the ion exchange chromatography method by commercial kit (Biosystem, Barcelona, Spain). The coefficient of variation (CV) for FPG was 1.3% and HbA1c was 5.1. Plasma concentration of pentosidine and CML was assessed using enzyme immunoassay (ELISA). Pentosidine and CML by related kits (Cusabio Biotech, Wuhan, China) were measured. Plasma concentration of MDA and total antioxidant capacity (TAC) were measured by colorimetry using kits (Cayman, Ann Arbor, USA; and Biocore diagnostics, Hamburg, Germany), respectively. The CV for pentosidine, CML, MDA, and TAC was 6.9, 7.8, 6.4, and 7.3, respectively.

Pomegranate and placebo juice {#S0002-S20005}
-----------------------------

To choose the commercial PJ with the highest polyphenol levels, several hand-squeezed and various commercially available juices were analyzed, using the colorimetric assay. The phenols were determined by the Folin--Ciocalteu reagent, using gallic acid as a standard and had 1,946 mg gallic acid equivalent (GAE)/L of PJ ([@CIT0013]). Total flavonoid content, measured by the aluminum chloride colorimetric assay, using catechin standard ([@CIT0014]), had 345.87 µg catechin equivalent/ml of PJ. The juice was diluted at 1:10 (v:v) to measure TAC, which is based on the inhibition percent of 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid), and when compared with bovine serum albumin (BSA) standard curve, it had 7 mmol/L BSA TAC ([@CIT0003]). PJ provides 126 kcal, 24 g sugar, and 1 g protein, while placebo beverage had similar color, taste, and energy content (126 kcal, 24 g sugar, and 1 g protein), but colorimetric assays showed that it has no polyphenols. The juice and the placebo were kept at room temperature (\<25°C) until opened as recommended by the manufacturer.

Statistical methods {#S0002-S20006}
-------------------

Statistical analysis of data was performed using the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) for Windows version 16.0. A *χ*^2^ test was used to compare qualitative variables between the two groups. Normality of quantitative parameters was tested using Kolmogorov--Smirnov test. Since all parameters had normal distributions, independent t-tests and paired t-tests were used to compare parameters between and within the groups, respectively. Adjustment for differences in baselines covariates and changes in variables during the study were performed by analysis of covariance (ANCOVA) using general linear models. The results were expressed as mean±SD, and differences were considered significant at *p*≤0.05.

Results {#S0003}
=======

There was no significant difference in baseline characteristics between the two groups. Anthropometrical factors did not differ between the two groups at the baseline or at the end of week 12 ([Table 1](#T0001){ref-type="table"}). In addition, these factors did not change significantly within the groups during the study. Dietary intakes of participants are shown in [Table 2](#T0002){ref-type="table"}. Energy and carbohydrate intake was different between the two groups.

###### 

Baseline and anthropometric characteristics of patients in the pomegranate juice and placebo groups

  Characteristics                                                 Pomegranate (*n*=22)   Placebo (*n*=22)
  --------------------------------------------------------------- ---------------------- ------------------
  Age (years)[a](#TF0001){ref-type="table-fn"}                    55±6.7                 56.9±6.8
  Duration of diabetes (years)[a](#TF0001){ref-type="table-fn"}   5.8±3.2                6.5±4.3
   Weight (kg)                                                    76.9±15                75.2±15
   BMI                                                            29.4±3.9               28.6±4.2
  Sex                                                                                    
   Men                                                            11 (50%)               12 (54.5%)
   Women                                                          11 (50%)               10 (45.5%)
  Anti-hypertensive drugs (%)                                                            
   ACE-I or ARB                                                   4 (18.2%)              6 (27.3%)
   Anti-hyperlipidemic drugs (%)                                  3 (13.6%)              4 (18.2%)

BMI: body mass index; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers.

Age and duration of diabetes are presented as mean±SD.

###### 

Dietary intakes of the pomegranate juice and placebo groups[a](#TF0002){ref-type="table-fn"}

  Intake               Groups        Baseline                                     Week 12
  -------------------- ------------- -------------------------------------------- --------------------------------------------
  Energy (kcal/d)      Pomegranate   1,784±238[b](#TF0003){ref-type="table-fn"}   1,787±233[b](#TF0003){ref-type="table-fn"}
                       Placebo       2,028±241                                    2,011±221
  Protein (g/d)        Pomegranate   54±12                                        58±12
                       Placebo       59±10                                        65±9
  Carbohydrate (g/d)   Pomegranate   234±35                                       266±41[b](#TF0003){ref-type="table-fn"}
                       Placebo       232±27                                       257±37
  Fiber (g/d)          Pomegranate   15±4                                         15±3
                       Placebo       16±3                                         15±4
  Fat (g/d)            Pomegranate   73±20                                        72±19
                       Placebo       84±15                                        83±19
  SAFA (g/d)           Pomegranate   16.2±5.5                                     17.2±6.4
                       Placebo       23.7±8.8                                     21.3±8.2
  MUFA (g/d)           Pomegranate   30.7±11                                      29.8±8.8
                       Placebo       32.5±6.1                                     33.6±8.7
  PUFA (g/d)           Pomegranate   21.4±6.7                                     19.4±4.4
                       Placebo       20.5±6.1                                     21.7±5.9
  Cholesterol (mg/d)   Pomegranate   134.3±60.7                                   136.1±48.6
                       Placebo       169.6±78                                     189.9±58.2
  Vitamin E (mg/d)     Pomegranate   22.7±5.9                                     20.7±4.7
                       Placebo       20.5±6.6                                     22.1±6.6
  Vitamin C (mg/d)     Pomegranate   78.7±54.3                                    77.3±32.9
                       Placebo       60.1±32.8                                    66.6±32.1
  Vitamin A (μg/d)     Pomegranate   559.7±478.3                                  719.9±609
                       Placebo       440.8±349.4                                  359.7±170.2

BMI: body mass index; MUFA: monounsaturated fatty acids; SAFA: saturated fatty acids; PUFA: polyunsaturated fatty acids.

All values are presented as mean±SD.

*n*=22 for all values.

*P*\<0.05 versus the placebo group.

At baseline, there was no significant difference in plasma TAC levels between the two groups, but MDA levels were significantly different (*p*=0.0001). Within the group, analysis showed that levels of MDA and TAC have changed significantly in the PJ group, compared with the baseline ([Table 3](#T0003){ref-type="table"}). Comparison of TAC between the two groups showed higher values in the PJ group when compared with the control group. ANCOVA was performed to compare MDA between two the groups using the baseline MDA values as the covariate. There was a significant difference between the two groups, indicating lower MDA levels in the PJ group.

At baseline, there were no differences in plasma concentrations of CML and pentosidine between the two groups. At the end of the study, no significant changes were found in plasma concentrations of CML or pentosidine between or within the groups.

###### 

Plasma concentrations of oxidative stress and AGE markers, fasting plasma glucose, and HbA1C in the pomegranate juice and placebo groups[a](#TF0004){ref-type="table-fn"}

  Parameters                        Groups        Baseline     Week 12                                 *P*-value   Mean change from baseline
  --------------------------------- ------------- ------------ --------------------------------------- ----------- ---------------------------
  MDA (µmol/L)                      Pomegranate   7.6±1.9      5.7±2.1                                 0.0001      −1.9±1.3
                                    Placebo       4.3±2.9      5.2±2.2                                 NS          0.85±2.3
  *P*-value (between groups)                      0.0001       0.01[b](#TF0005){ref-type="table-fn"}               
  TAC (U/ml)                        Pomegranate   22.8±6.4     27.4±6.8                                0.001       4.6±5.8
                                    Placebo       19.8±4.8     20.7±6.6                                NS          0.9±4.2
  *P*-value (between groups)                      NS           0.002                                               
  Carboxy methyl lysine (nmol/ml)   Pomegranate   1.7±0.6      1.5±0.4                                 NS          −0.2±0.6
                                    Placebo       1.7±0.3      1.5±0.5                                 NS          −0.2±0.5
  *P*-value (between groups)                      NS           NS                                                  
  Pentosidine (pmol/ml)             Pomegranate   49±53        59±46                                   NS          10.2±53.3
                                    Placebo       79±83        65±46                                   NS          −14.3±72.5
  *P*-value (between groups)                      NS           NS                                                  
  Fasting plasma glucose (mg/dl)    Pomegranate   160.3±47.8   162±35.2                                NS          2±45.3
                                    Placebo       148.7±42.1   158.6±49.1                              NS          9.8±43.3
  *P*-value (between groups)                      NS           NS                                                  
  HbA1C (%)                         Pomegranate   8.4±1.2      8.1±1.1                                 NS          −0.3±0.6
                                    Placebo       7.5±1.1      7.3±0.1                                 NS          −0.2±0.4
  *P*-value (between groups)                      NS           NS                                                  

MDA: malondialdehyde; TAC: total antioxidant capacity; NS: non-significant.

All values are presented as mean±SD.

*n*=22 for all values.

ANCOVA was performed using baseline values as covariate.

Discussion {#S0004}
==========

The results of the current study indicate that daily consumption of PJ could increase plasma TAC and decrease plasma MDA in diabetic patients while it has no effect on AGE levels. Juice extracted from the pomegranate has been shown to have the greatest *in vitro* antioxidant potency among commonly consumed beverages ([@CIT0008], [@CIT0015]). It is worth mentioning that the baseline MDA levels in the PJ group were higher than in the placebo group. Therefore, in addition to antioxidative properties of PJ that could influence plasma MDA level, part of the decline in MDA levels following PJ consumption could be due to the higher baseline levels of MDA in the PJ group. Increased serum TAC and paraoxonase and decreased LDL sensitivity to oxidation have been reported in healthy persons ([@CIT0011]) and patients with carotid arterial stenosis following PJ consumption ([@CIT0016]). Pomegranate is known as a very rich source of anthocyanins, ellagic acid, punicalagins, catechins, and gallocatechins ([@CIT0015], [@CIT0017], [@CIT0018]). Anthocyanin-rich beverage ingestion has been reported to decrease plasma and urinary concentrations of MDA and to improve plasma antioxidant capacity in healthy female volunteers ([@CIT0019]). Furthermore, ellagic acid has been shown to reduce MDA levels in the brain of streptozotocin-induced diabetic rats ([@CIT0020]). Consumption of pomegranate polyphenolic extract has led to a significant decrease in serum MDA in diabetic patients ([@CIT0021]). In addition, the juice has been shown to decrease serum lipid peroxides and increase paraoxonase ([@CIT0022]). Although polyphenolic extract of PJ is effective in reducing oxidative stress, the extract is less potent than the juice, which may indicate that other factors in the juice (unique sugars) may contribute to mitigate oxidative stress ([@CIT0022]). The mechanism by which PJ or its compounds could ameliorate lipid peroxidation and oxidative stress is not well known but might occur by directly neutralizing the generated reactive oxygen species ([@CIT0023]), increasing certain antioxidant enzyme activities such as paraoxonase ([@CIT0022]), and inhibiting or activating certain transcriptional factors, such as nuclear factor *κ*B ([@CIT0024], [@CIT0025]) and peroxisome proliferator-activated receptor *γ* ([@CIT0026]). Interestingly, a recent study showed that administration of pomegranate fruit extract for seven consecutive days before and after methotrexate challenge in Swiss albino mice reduced ROS generation in hepatocytes mainly by differential regulation of the activation of the transcription factors nuclear factor (erythroid-derived 2)-like 2 and nuclear factor *κ*B as a consequence of which the antioxidant defense mechanism in the liver was upregulated ([@CIT0024]).

Protein glycation and AGE formation are the result of non-enzymatic reactions with glucose; AGE level has previously correlated with HbA1c levels ([@CIT0027], [@CIT0028]). Serum levels of pentosidine and CML have been reported to be higher in patients with type 2 diabetes, compared with non-diabetic controls ([@CIT0029]). In addition, during the process of AGE formation, ROS are produced as by-products of the late steps of glycation reactions, and these radicals in turn further promote glycation ([@CIT0030]). AGE levels have been associated with ROS in diabetic patients ([@CIT0031]). Previously, *in vitro* and animal studies have shown that polyphenolic extracts from a different source could inhibit AGE formation ([@CIT0032], [@CIT0033]). In our study, although we found that PJ resulted in a significant improvement in TAC an MDA status, there was no significant difference between the PJ group and the placebo group regarding plasma concentration of pentosidine and CML. One possible explanation for this finding is that the patients in the current study did not have such elevated baseline AGE levels. In a study by Lapolla et al., plasma pentosidine levels of a healthy subject were 63.2 pmol/ml which are comparable to the pentosidine levels of our study subjects, while in diabetic patients without peripheral artery disease pentosidine levels were 85.5 pmol/ml and in those with peripheral artery disease were 109.2 pmol/ml ([@CIT0006]). Since no significant difference were found in glycemic control between the two groups, comparable non-enzymatic reaction with glucose and protein glycation could have occurred in both the groups. Another possibility is that to influence plasma AGEs, taking antioxidant source should continue for a more prolonged time. In a study by Shimada et al., antioxidant therapy for 6 months significantly decreased hemoglobin carboxymethyl valine residue levels, though HbA1c did not change ([@CIT0034]).

In the current study, although dietary energy and carbohydrate intake differed between the two groups, no significant changes in body weight, plasma glucose, or HbA1c were observed between the two groups.

Some limitations of the present study are that PJ consumption was relatively short in duration and few parameters reflecting oxidative stress and advanced glycation process were measured.

In conclusion, 12-week consumption of PJ does not influence plasma levels of the AGEs, pentosidine and CML, in patients with T2D while it improved plasma TAC an MDA status. PJ contain simple sugars. However, its consumption did not impair glycemic control of diabetic patients. Therefore, it could be potential natural drinks in diabetic diet with favorable properties.
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